Riskpilot← Back to searchSign inGet full accessDIAGEN AS
ASActiveOrg 987520590Mosseveien 60, 1640 RådeWholesale of pharmaceutical and medical goods · NACE 4646Est. 20048 employeeswww.diagen.no
Revenue 2024
NOK 13,5M
+63% vs 2023
EBITDA margin
-23.0%
+58% vs 2023
Equity ratio
27.6%
Financial strength
Net profit 2024
NOK -8M
-154% vs 2023
| Revenue | NOK 13,5M | +63% |
| EBITDA | NOK -3,1M | +58% |
| Net profit | NOK -8M | -154% |
| Total assets | NOK 26,2M | -43% |
| Equity | NOK 7,2M | -50% |
| Employees | 8 | — |
Legal name
DIAGEN AS
Org number
987520590
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
24. november 2004
Share capital
NOK 100 000
Employees
8 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Handelsvirksomhet, samt annen virksomhet som naturlig faller inn under dette, inkludert deltakelse med andre selskaper med lignende virksomheter.
Address
Mosseveien 60, 1640 Råde
Website
www.diagen.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 221 196 | 78 581 | 18 235 | 8 288 | 13 508 |
| Staff expenses | −6 808 | −6 881 | −8 380 | −7 846 | −7 099 |
| EBITDA | 115 975 | 35 878 | −2 293 | −7 338 | −3 102 |
| Depreciation & amort. | −1 055 | −1 230 | −3 498 | −564 | −489 |
| EBIT | 114 919 | 34 648 | −5 791 | −7 902 | −3 591 |
| Net financials | 45 772 | 55 410 | −655 | 22 539 | −4 366 |
| Profit before tax | 160 691 | 90 058 | −6 446 | 14 636 | −7 957 |
| Tax | 26 189 | 6 159 | −210 | −0 | −0 |
| Net profit | 134 503 | 83 899 | −6 236 | 14 636 | −7 957 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 283 964 | 245 013 | 83 265 | 45 827 | 26 185 |
| Equity | 109 908 | 7 810 | 1 574 | 14 565 | 7 220 |
| Long-term debt | 20 994 | 210 | 77 363 | 22 713 | 9 209 |
| Short-term debt | 153 062 | 236 993 | 4 328 | 8 549 | 9 756 |
| Total debt | 174 056 | 237 203 | 81 691 | 31 262 | 18 965 |
EBITDA margin
-23.0%
This company
15.8%
Market median
-246% vs market
20202024
Equity ratio
27.6%
This company
38.2%
Market median
-28% vs market
20202024
Return on equity
-110.2%
This company
18.4%
Market median
-699% vs market
20202024
Net profit margin
-58.9%
This company
8.1%
Market median
-827% vs market
20202024
Asset turnover
0.52×
This company
1.12×
Market median
-54% vs market
20202024
Debt / equity
2.63×
This company
0.62×
Market median
-324% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
VK Deputy Member | Deputy Member | 2005 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2005 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Diagen International Inc. As
DIAGEN AS Board members of DIAGEN AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Vegard Kjærheim | Deputy Member | 0 companies |
| Vidar Lindberg | Chairman | 0 companies |